Incidence and survival of rare cancers in the US and Europe
Incidence and survival of rare cancers in the US and Europe
复制标题
DOI：
10.1002/cam4.3137
复制
发表时间：
2020-05-21
期刊：
影响因子：
4
通讯作者：
Mariotto, Angela B.
中科院分区：
文献类型：
--
作者：
Botta, Laura;Gatta, Gemma;Mariotto, Angela B.
癌症负担的地理差异几乎完全是针对常见癌症进行估计的。由于罕见癌症（RC）已成为基础和临床研究和公共卫生组织的优先领域，本文提供了一个通用的方法，详细比较RC在美国和欧洲的发病率和生存率。我们从18个US-SEER和94个欧洲登记处收集的258万例患者的数据中估计了199例恶性RC的发病率和净生存率，这些患者在最近的共同期2000-2007年内诊断。RC是根据65岁以上的粗年发病率标准定义的。使用标准化方法证明，美国大多数RC的发生率和生存率高于欧洲。需要进一步研究的这种差异的可能原因包括风险因素的分布，诊断RC的能力，不同的注册实践以及使用更新的国际肿瘤疾病分类。
Geographical variability of cancer burden was almost exclusively estimated for common cancers. Since rare cancers (RC) have become an area of priority for basic and clinical research and public health organizations, this paper provides, using a common methodology, a detailed comparison of incidence and survival for RC in the US and Europe. We estimated incidence and net survival of 199 malignant RC from data of 2 580 000 patients collected by 18 US-SEER and 94 European registries, diagnosed within the most recent common period 2000-2007. RC were defined according to the criterion of crude annual incidence rates 65+ years of age. Use of standardized methods evidenced that incidence and survival rate of majority of RC were higher in the United States compared to Europe. Possible reasons for such differences, requiring further studies, include distribution of risk factors, ability to diagnose RC, different registration practices, and use of updated International Classification of Diseases for Oncology.